Lisa Drew

4.4k total citations · 1 hit paper
55 papers, 2.2k citations indexed

About

Lisa Drew is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Lisa Drew has authored 55 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 27 papers in Oncology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Lisa Drew's work include Cancer-related Molecular Pathways (14 papers), Cell death mechanisms and regulation (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). Lisa Drew is often cited by papers focused on Cancer-related Molecular Pathways (14 papers), Cell death mechanisms and regulation (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). Lisa Drew collaborates with scholars based in United States, United Kingdom and Brazil. Lisa Drew's co-authors include Jamal Saeh, Lecia V. Sequist, A. John Iafrate, Benjamin Solomon, Balázs Halmos, Katherine Crosby, John C. Wain, Cyril H. Benes, Tahsin Khan and Alice T. Shaw and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Lisa Drew

54 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

2012 976 citations Lisa Drew et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa Drew United States	18	1.4k	1.2k	882	311	289	55	2.2k
Cornelia Quadt Switzerland	25	1.4k 1.0×	756 0.6×	591 0.7×	273 0.9×	208 0.7×	53	2.2k
Kristen E. Mengwasser United States	7	1.5k 1.1×	1.1k 0.9×	1.1k 1.2×	523 1.7×	147 0.5×	8	2.4k
Tomislav Dragovich United States	24	1.0k 0.8×	1.1k 0.9×	548 0.6×	444 1.4×	230 0.8×	80	2.3k
Josef Brueggen Switzerland	10	1.8k 1.3×	633 0.5×	348 0.4×	381 1.2×	239 0.8×	14	2.4k
Robert J. Mullin United States	19	1.2k 0.9×	1.9k 1.6×	785 0.9×	301 1.0×	124 0.4×	37	3.0k
Silvia La Monica Italy	32	1.1k 0.8×	1.2k 1.0×	1.0k 1.2×	367 1.2×	155 0.5×	67	2.2k
Shundong Cang China	21	1.4k 1.0×	779 0.6×	679 0.8×	485 1.6×	229 0.8×	80	2.3k
Scott A. Boerner United States	23	1.2k 0.9×	852 0.7×	337 0.4×	334 1.1×	195 0.7×	40	2.2k
Uzma Asghar United Kingdom	11	923 0.7×	1.6k 1.3×	1.3k 1.5×	491 1.6×	249 0.9×	25	2.4k
Roberta Minari Italy	25	1.1k 0.8×	1.5k 1.2×	1.7k 1.9×	585 1.9×	208 0.7×	66	2.5k

Countries citing papers authored by Lisa Drew

Since Specialization

Citations

This map shows the geographic impact of Lisa Drew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Drew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Drew more than expected).

Fields of papers citing papers by Lisa Drew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Drew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Drew. The network helps show where Lisa Drew may publish in the future.

Co-authorship network of co-authors of Lisa Drew

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Drew. A scholar is included among the top collaborators of Lisa Drew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Drew. Lisa Drew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wen, Shenghua, Graeme Scarfe, Justin Cidado, et al.. (2023). A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models. The AAPS Journal. 25(4). 66–66. 1 indexed citations

Oien, Derek B., Samanta Sharma, Maureen M. Hattersley, et al.. (2023). BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5. Blood Advances. 7(17). 5108–5121. 7 indexed citations

Criscione, Steven W., Matthew J. Martin, Derek B. Oien, et al.. (2022). The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells. npj Precision Oncology. 6(1). 95–95. 22 indexed citations

Grimster, Neil P., Lisa Drew, Stephen E. Fawell, et al.. (2020). Abstract A56: Releasing the brake on T-cell activation through inhibition of HPK1. Cancer Immunology Research. 8(3_Supplement). A56–A56. 1 indexed citations

Danilova, Olga V., Erin Gilbert, Craig Okada, et al.. (2019). Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma. Molecular Cancer Therapeutics. 18(9). 1520–1532. 40 indexed citations

Boiko, Scott, Theresa A. Proia, Maryann San Martin, et al.. (2019). Abstract 2500: Transient CDK9 inhibition with AZD4573 modulates Bfl-1 in preclinical lymphoma models. Cancer Research. 79(13_Supplement). 2500–2500. 1 indexed citations

Ma, Rui, Ling Xu, Xiujuan Qu, et al.. (2018). AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status. British Journal of Cancer. 118(11). 1453–1463. 12 indexed citations

Degorce, Sébastien L., Rana Anjum, Keith Dillman, et al.. (2018). Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4. Bioorganic & Medicinal Chemistry. 26(4). 913–924. 15 indexed citations

Koch, Raphael, Amanda L. Christie, Jennifer L. Crombie, et al.. (2018). Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 133(6). 566–575. 35 indexed citations

10.

Scott, David A., Les A. Dakin, David J. Del Valle, et al.. (2013). Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507. Bioorganic & Medicinal Chemistry Letters. 23(16). 4591–4596. 17 indexed citations

11.

Scott, David A., Les A. Dakin, David J. Del Valle, et al.. (2011). 3-Amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor. Bioorganic & Medicinal Chemistry Letters. 21(5). 1382–1384. 38 indexed citations

12.

Montagut, Clara, Sreenath V. Sharma, Toshi Shioda, et al.. (2008). Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma. Cancer Research. 68(12). 4853–4861. 405 indexed citations

13.

Lyne, Paul D., Brian Aquila, Les A. Dakin, et al.. (2008). Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity. Bioorganic & Medicinal Chemistry Letters. 19(3). 1026–1029. 7 indexed citations

14.

Scott, David A., Kirsten Bell, Les A. Dakin, et al.. (2008). 3-Amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile. Bioorganic & Medicinal Chemistry Letters. 19(3). 701–705. 19 indexed citations

15.

Drew, Lisa, et al.. (2007). Trip to Haiti changes lives of patients and volunteers.. PubMed. 88(5). 62–5. 4 indexed citations

16.

Drew, Lisa, Daniel P. Petrylak, Yuehua Mao, et al.. (2007). Activation of Targeted Necrosis by a p53 Peptide. Journal of Biological Chemistry. 282(37). 26675–26686. 16 indexed citations

17.

Rosal, Ramon, Lisa Drew, Anthony J. Raffo, et al.. (2003). Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene. 22(10). 1431–1444. 65 indexed citations

18.

Merritt, Janet E., John A. Sullivan, Lisa Drew, et al.. (1999). The bisindolylmaleimide protein kinase C inhibitor, Ro 32-2241, reverses multidrug resistance in KB tumour cells. Cancer Chemotherapy and Pharmacology. 43(5). 371–378. 19 indexed citations

19.

Drew, Lisa. (1998). Inhibition of the protein kinase C pathway promotes anti-CD95-induced apoptosis in Jurkat T cells. International Immunology. 10(7). 877–889. 27 indexed citations

20.

Rumsby, Martin G., Lisa Drew, & J.R. Warr. (1998). Protein kinases and multidrug resistance. Cytotechnology. 27(1-3). 203–224. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact